Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

CEO and President

Chief Legal Officer

Chief Medical Officer

Chief Operating Officer

See Remarks

Chief Development Officer

Chief Financial Officer

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, a novel oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatm...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-02-05	Premium	sold	Premium	Premium	Premium	CEO and President
2024-02-02	Premium	sold	Premium	Premium	Premium	CEO and President
2024-02-02	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2024-02-02	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2024-02-02	Premium	sold	Premium	Premium	Premium	-
2024-02-02	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2024-02-01	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2024-02-01	Premium	acquired	Premium	Premium	Premium	See Remarks
2024-02-01	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-02-01	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2024-02-01	Premium	acquired	Premium	Premium	Premium	CEO and President
2023-11-13	Premium	acquired	Premium	Premium	Premium	See Remarks
2023-10-05	Premium	acquired	Premium	Premium	Premium	-
2023-10-05	Premium	acquired	Premium	Premium	Premium	-
2023-10-05	Premium	acquired	Premium	Premium	Premium	-
2023-10-05	Premium	acquired	Premium	Premium	Premium	-
2023-10-05	Premium	acquired	Premium	Premium	Premium	-
2023-10-05	Premium	acquired	Premium	Premium	Premium	-
2023-10-05	Premium	acquired	Premium	Premium	Premium	-
2023-10-05	Premium	acquired	Premium	Premium	Premium	-
2023-09-13	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-08-29	Premium	sold	Premium	Premium	Premium	CEO and President
2023-08-28	Premium	sold	Premium	Premium	Premium	CEO and President
2023-08-28	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2023-08-28	Premium	sold	Premium	Premium	Premium	Chief Development Officer

SPRO - Spero Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for SPRO